Breakthrough in Triple Therapy Approach for Advanced Breast Cancer: Balancing Promise and Challenges

Exploring a Novel Triple Approach in Breast Cancer Treatment?

A phase Ib trial has established the maximum tolerated dose for the triple combination of erdafitinib, fulvestrant, and palbociclib in hormone receptor-positive (HR+) HER2-negative metastatic breast cancer patients. The study, conducted across five institutions, determined that 6 mg of erdafitinib can be safely combined with standard doses of fulvestrant and palbociclib, though with notable toxicity concerns that may limit widespread implementation.

The trial enrolled 35 post-menopausal women with HR+/HER2-negative metastatic breast cancer who had previously received CDK4/6 inhibitor therapy. Researchers employed a traditional 3+3 design to evaluate escalating doses of erdafitinib (5 mg, 6 mg, and 8 mg) in combination with fulvestrant and palbociclib. Dose-limiting toxicities were observed in one out of six patients at 6 mg and three out of four patients at 8 mg, establishing 6 mg as the maximum tolerated dose. The most common adverse events included neutropenia (likely attributable to palbociclib), oral mucositis, and hyperphosphatemia (attributable to erdafitinib). Seven patients (20%) discontinued treatment due to toxicities, primarily associated with erdafitinib. Despite the rationale for targeting FGFR pathway aberrations in this patient population, clinical efficacy was modest with an overall response rate of 10% and median progression-free survival of 12 weeks.

What Underpins the Preclinical Rationale for this Combination?

The study builds on preclinical evidence suggesting that FGFR pathway signaling aberrations, found in approximately 15% of HR+ breast cancers, are associated with poor prognosis and resistance to endocrine therapy and CDK4/6 inhibitors. Previous laboratory studies had demonstrated that adding an FGFR inhibitor could restore sensitivity to palbociclib and fulvestrant in FGFR1-amplified drug-resistant models. However, translating these findings to clinical benefit has proven challenging. "Despite several FGFR inhibitors being evaluated in both the preclinical and clinical space in patients with breast cancer, none have been approved by the Food and Drug Administration to treat breast cancer," the investigators noted in their report.

An important aspect of the study was the attempt to identify biomarkers predictive of response to FGFR inhibition. Contrary to expectations, FGFR1 amplification alone did not reliably predict response to treatment. Interestingly, patients with high FGFR1 protein expression by immunohistochemistry within the FGFR1-amplified cohort exhibited extended progression-free survival compared to those with low expression (median PFS 21.43 vs. 12.21 weeks). However, the correlation between FGFR1 gene amplification and protein expression was modest, particularly in samples from metastatic sites. This finding challenges the assumption that FGFR1 amplification necessarily leads to protein overexpression and tumor dependence on FGFR1 signaling.

The investigators noted one exceptional responder who maintained a partial response for over 2.5 years despite lacking detectable FGFR1-4 genetic alterations. This patient's tumor exhibited amplifications in 11q13 (harboring CCND1, FGF3, FGF4, and FGF19), CRKL, ZNF217, and AURK, as well as a BRCA1 Q687P mutation. Such outlier responses highlight the complexity of predicting benefit from targeted therapies and suggest that alternative biomarkers or combination strategies may be necessary to fully capitalize on FGFR inhibition in breast cancer.

How Can These Insights Shape Future Therapeutic Strategies?

The findings from this trial align with previous studies of FGFR inhibitors in breast cancer, which have shown mixed results. Early-phase clinical trials with multi-target pan-FGFR tyrosine kinase inhibitors, either alone or in combination with antiestrogens, have demonstrated limited clinical benefit. The investigators suggested that alternative approaches might include sequential treatment with doublets of FGFR inhibitors and SERDs followed by FGFR and CDK4/6 antagonist combinations, potentially avoiding the toxicity associated with triplet therapy. They concluded that while FGFR inhibitors may still have a role in treating CDK4/6 inhibitor-refractory HR+ breast cancers, both FGFR1-selective inhibitors and reliable biomarkers of FGFR1 dependence remain unmet needs.

The toxicity profile observed in this study was more severe than that reported in the phase III PALOMA 3 trial, which evaluated the combination of palbociclib and fulvestrant. However, the investigators noted that patients in PALOMA III had not received prior CDK4/6 inhibitors and generally had fewer prior therapies. Interestingly, the three patients who achieved a partial response in the current study underwent dose reductions due to toxicities and received reduced doses of erdafitinib (4 mg) and palbociclib (75-100 mg) along with standard-dose fulvestrant (500 mg) during the period when partial response was achieved. This observation suggests that lower doses might offer a more favorable toxicity profile while maintaining clinical benefit.

Erdafitinib was recently approved as a single agent for the treatment of locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations. While this approval demonstrates the potential of FGFR inhibition in certain cancer types, the path forward in breast cancer appears more complex. The investigators emphasized the importance of contemporary biopsies for biomarker analysis to increase the likelihood that a current biomarker is valid and predictive of response. They also highlighted the need for more selective FGFR inhibitors that might offer improved efficacy with reduced toxicity.

Industry Context

This trial reflects the ongoing challenge in oncology drug development of translating promising preclinical findings into clinical benefit. While targeted therapies have revolutionized cancer treatment across multiple tumor types, identifying the right patients and optimal drug combinations remains difficult. The modest efficacy observed with this triplet combination, despite strong preclinical rationale, underscores the complexity of tumor biology and drug resistance mechanisms. As pharmaceutical companies continue to develop next-generation targeted therapies, including more selective FGFR inhibitors, the emphasis on robust biomarker development and rational combination strategies will be critical for success in the increasingly crowded oncology market.

Summary

The phase Ib trial determined that 6 mg of erdafitinib can be safely combined with standard doses of fulvestrant and palbociclib in HR+/HER2-negative metastatic breast cancer patients. The study involved 35 post-menopausal women who had previously received CDK4/6 inhibitor therapy. While the combination showed modest clinical efficacy with a 10% response rate and 12-week median progression-free survival, significant toxicity issues were observed. The research revealed that FGFR1 amplification alone doesn't reliably predict treatment response, though high FGFR1 protein expression within FGFR1-amplified cases showed improved outcomes. The findings suggest that alternative approaches, such as sequential treatment or lower doses, might be more practical for future therapeutic strategies.